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Mesenchymal stromal cells (MSCs) tend to infiltrate
into tumors and form amajor component of the tumor
microenvironment. These tumor-resident MSCs are
known to affect tumor growth, but the mechanisms
are largely unknown. We found that MSCs isolated
from spontaneous lymphomas in mouse (L-MSCs)
strikingly enhanced tumor growth in comparison to
bonemarrowMSCs (BM-MSCs). L-MSCscontributed
to greater recruitment of CD11b+Ly6C+ monocytes,
F4/80+ macrophages, and CD11b+Ly6G+ neutrophils
to the tumor. Depletion of monocytes/macrophages,
but not neutrophils, completely abolished tumor
promotion of L-MSCs. Furthermore, L-MSCs ex-
pressed high levels of CCR2 ligands, and monocyte/
macrophage accumulation and L-MSC-mediated
tumor promotion were largely abolished in CCR2/
mice. Intriguingly, TNFa-pretreated BM-MSCs mim-
icked L-MSCs in their chemokine production profile
and ability to promote tumorigenesis of lymphoma,
melanoma,andbreastcarcinoma.Therefore, ourfind-
ings demonstrate that, in an inflammatory environ-
ment, tumor-resident MSCs promote tumor growth
by recruiting monocytes/macrophages.
INTRODUCTION
Mesenchymal stromal cells (MSCs) exist in almost all types of
tissues and are believed to play a central role in tissue regener-
ation, wound repair, and maintenance of tissue homeostasis812 Cell Stem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier In(Jiang et al., 2002; Pittenger et al., 1999; Prockop, 1997). In vivo
administration of MSCs has been shown to be highly effective in
the treatment of various immune disorders and degenerative
diseases in both animal models and humans (Caplan, 2007;
Uccelli et al., 2008). It was recently demonstrated that there is
a close interaction between MSCs and the immune system
(Shi et al., 2010, 2012). MSCs have been shown to interact
with a variety of immune cells including T cells, B cells, dendritic
cells, monocytes/macrophages, and natural killer cells, as well
as serving as a major niche component for hematopoietic
stem/progenitor cells in the bone marrow (English et al., 2010;
Me´ndez-Ferrer et al., 2010).
MSCs are one of the major components of the tumor
stroma and are also believed to be the precursors of tumor-
associated fibroblasts (Mishra and Merlino, 2008; Quante
et al., 2011; Spaeth et al., 2009; Studeny et al., 2004). Tumors
have long been regarded as wounds that do not heal (Riss
et al., 2006), and they are usually infiltrated with multiple
types of immune cells, which, together with supporting
stromal cells, comprise the tumor microenvironment (White-
side, 2008). Because tumor-resident MSCs are often con-
stantly exposed to immune cells and inflammatory cytokines/
chemokines in the tumor microenvironment, they may have
acquired functions that are distinct from those of normal tissue
MSCs, and these unique functions may play a role in modu-
lating the tumor microenvironment and ultimately affect tumor
progression. Some recent studies have indicated that through
secretion of certain soluble factors such as chemokine
CCL-5, MSCs could promote cancer cell metastasis (Karnoub
et al., 2007), though the detailed mechanisms through which
MSCs acquire their metastasis-promoting function are largely
unknown.
Most of the studies referenced above employed xenotrans-
planted tumors in immunodeficient mice. While these modelsc.
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and human tumor development, lack of adaptive immune cells
hampers a systematic understanding of how the interaction
between MSCs and both the adaptive and innate immune
systems might impact tumor progression. In the current study,
we isolated tumor stromal MSCs (lymphoma-derived MSCs;
L-MSCs) from spontaneously developed lymphomas, charac-
terized their tumor-promoting activity in a syngeneic tumor
transplantation model, and studied their influence on the host
adaptive and innate immune responses in comparison to normal
tissue MSCs (bone marrow-derived MSCs; BM-MSCs). Our
results show that while L-MSCs behaved not differently from
BM-MSCs in their effects on adaptive immune cells, they
were more effective in recruiting monocytes/macrophages via
CCR2, thus exerting a much stronger tumor promoting effect
than BM-MSCs. Importantly, BM-MSCs exposed to TNFa also
acquired these properties of L-MSCs. Therefore, this study
reveals a mechanism through which tumor mesenchymal
stromal cells promote tumor progression and implicates inflam-
matory cytokines in the promalignant conversion of these
stromal cells.
RESULTS
Lymphoma-DerivedMSCs Promote Tumor GrowthMore
Potently than Do BM-MSCs
Tumor-resident MSCswere derived from lymphomas that devel-
oped spontaneously in mice bearing mutations in p53 (p53/ or
p53+/) (Donehower et al., 1992), FasL (gld /gld) (Davidson et al.,
1998), andMutL homolog 1 (Mlh1/) (Prolla et al., 1998). Unlike
sarcoma or carcinoma cells, lymphoma cells are nonadherent
in tissue culture and thus can be easily separated from tumor-
resident MSCs, which adhere well to tissue culture plastic. We
obtained several lines of L-MSCs, according to a modified
protocol for isolating BM-MSCs (Ren et al., 2008b). For controls,
BM-MSCs were also isolated from the same mutant mice. Like
BM-MSCs, L-MSCs showed spindle-likemorphology (Figure 1A)
and were multipotent, as demonstrated by their ability to differ-
entiate into adipocytes and osteoblasts under appropriate
conditions (see Figure S1A available online). Both cell types
had similar colony-forming capacity (Figure S1B) and were
phenotypically similar, being CD29+ CD44+Sca-1+CD140a+
CD31C-kitCD45CD11bCD11cF4/80 (Figure 1B). The
low expression of vimentin and fibroblast-specific protein 1
(FSP1) (Figure 1B) suggests that these lymphoma-associated
MSCs were distinct from myofibroblasts that often exist in
tumor stroma (Mishra et al., 2008; Spaeth et al., 2009). We
employed LinlowSca-1+CD140a+ to identify in vivo lymphoma-
associated MSCs (Morikawa et al., 2009) and found that this
cell population accounted for 0.01%–1% of the total tumor
cells in spontaneous lymphomas (Figure S1C). When the
LinlowSca-1+CD140a+ cells were sorted out and cultured
in vitro, they were similar to in vitro expanded L-MSCs in their
phenotype, differentiation potential, and functions in vitro and
in vivo (data not shown).
To determine whether L-MSCs could promote tumor growth,
we injected different L-MSC lines isolated from primary
lymphomas that formed in p53+/, gld/gld, or Mlh1/ mice
(all C57BL/6 background) into the hind legs of immunocompe-Celltent syngeneic C57BL/6 mice along with EL4 cells, a T cell
lymphoma line also derived from C57BL/6 mice. BM-MSCs iso-
lated from the same lymphoma-bearing mice or corresponding
wild-type mice were used as controls. When coinjected with
EL4 cells, L-MSCs, but not BM-MSCs, strikingly enhanced
tumor growth, while neither BM-MSCs nor L-MSCs alone eli-
cited tumor formation (Figure 1C and data not shown). In this
tumor transplantation model, MSCs did not expand after infu-
sion; however, tumor cells did proliferate vigorously. On day
7 (early to middle stages of EL4 tumor development), the
frequency of administered MSCs as a percentage of total cells
reached levels normally occurring in spontaneous lymphomas
(data not shown).
We also tested the effect of MSCs derived from other normal
adult mouse tissues such as skin. Similar to BM-MSCs, they
failed to exhibit a tumor-promoting effect (Figure S1D), suggest-
ing that, although phenotypically similar to MSCs from normal
tissues, L-MSCs were distinct in their tumor-promoting activity.
Meanwhile, the genetic abnormalities in specific genes (p53,
mlh1, or fasl) in MSCs did not account for the tumor-promotion
activity by L-MSCs, as BM-MSCs and skin-derived MSCs from
these mice did not significantly affect tumor growth (Figure 1C
and Figure S1D). Additionally, L-MSCs isolated from wild-type
hosts bearing syngeneic EL4 lymphomas also enhanced tumor
growth compared to BM-MSCs, although this effect was less
robust than occurred with L-MSCs from primary tumors
(Figure S1E).
Previous studies have shown that BM-MSCs also favor tumor
growth (Djouad et al., 2003; Zhu et al., 2006). In our experiments,
BM-MSCs did not promote tumor growth at a ratio of 1:5 (MSCs
to tumor cells) (Figure 1C). However, at higher ratios (e.g., 2:5),
BM-MSCs also significantly promoted tumor growth, though
not to the same extent as L-MSCs (Figure 1D). Furthermore,
multiple administrations of BM-MSCs at low numbers also led
to a significant tumor promotion, although such potential was
much higher for L-MSCs (Figure S1F). Therefore, L-MSCs dis-
played greater potential to promote tumor growth in comparison
to BM-MSCs.
L-MSCs and BM-MSCs Similarly Modulate the Host
Adaptive Immune System
It has been reported that immune cells and the inflammatory
cytokines that they produce may dictate the function of MSCs
(Liu et al., 2011; Ren et al., 2008b). Since adaptive and innate
immune cells reside in great abundance in the tumor microenvi-
ronment at every stage of tumor progression, they probably
interact with MSCs residing in the same compartment and
modulate their function. To investigate how L-MSCs achieve
their tumor-promoting effect and how they differ from normal
tissue MSCs, we examined the interactions between MSCs
and the host immune system. Considering that L-MSCs from
all tested sources of mouse mutants produced similar results,
the data using p53+/ mouse lymphoma-derived L-MSCs are
presented as a representative in the following sections. BM-
MSCs isolated from syngeneic C57BL/6 mice at similar passage
numbers were used as controls.
We first monitored several subpopulations of lymphocytes
over 12 days, including CD3+ T cells, CD4+ and CD8+ subsets,
and CD19+ B cells in both peripheral blood and at tumor sitesStem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier Inc. 813
Figure 1. L-MSCs Promoted Lymphoma Growth to a Greater Extent than Did BM-MSCs
(A) Morphology of cultured L-MSCs from lymphoma-bearing p53+/ mice at passage 1 and passage 5.
(B) L-MSCs are phenotypically similar to BM-MSCs. After isolation from BM and lymphoma tumors, respectively, BM-MSCs and L-MSCs, each from passage 5,
were analyzed for the indicated markers by immunofluorescence staining and flow cytometry.
(C) Effect of coadministration of small number of MSCs on growth of EL4 lymphoma. EL4 cells were coadministered with BM-MSCs or L-MSCs from p53+/,
gld/gld, or mlh1/ mice or BM-MSCs from the respective wild-type mice at a 1:5 ratio (1 3 105 MSCs and 5 3 105 EL4 cells) into WT C57BL/6 mice by
intramuscular injection. After 12 days, tumors were excised and weighed.
(D) Impact of coadministration of large number of MSCs on lymphoma progression. A representative L-MSC line established from a lymphoma that developed
spontaneously in a p53+/mouse, or BM-MSCs derived from correspondingWTmice, were coinjected with EL4 cells at a 2:5 ratio (23 105MSCs and 53 105 EL4
cells) into C57BL/6mice. On days 6, 9, and 12, tumor size wasmeasured (mean ± SD), and tumors from day 12 were sectioned and imagedmicroscopically. Four
mice per treatment group were used and results are representative of three independent experiments.
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BM-MSCs or L-MSCs. In both peripheral blood and tumor
tissues, T cell and B cell numbers were strikingly reduced by
administration of either BM-MSCs or L-MSCs. Surprisingly,
L-MSCs and BM-MSCs were equally effective in reducing
lymphocytes at all time points tested (Figure 2A). Kinetically,
the greatest drop in cell numbers occurred in peripheral blood
from day 6 to day 9, the middle stage of tumor progression,
and cell losses continued during the later stage, from days 9 to
12 (Figure 2A). Moreover, IFNg and IL-12, important cytokines
in initiating cellular immunity against tumor, were equally
reduced by BM-MSC and L-MSC treatments (Figure 2B). Thus,
while L-MSCs have a more potent tumor-promoting capacity
than BM-MSCs, this effect is not caused by inhibition of the
adaptive immune response.814 Cell Stem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier InWe previously reported that mouse BM-MSCs suppress
T cell function by producing nitric oxide (NO) in response to
the proinflammatory cytokines, IFNg in combination with
TNFa, IL-1a, or IL-1b (Ren et al., 2008b). It might be possible
that BM-MSCs and L-MSCs differ in their production of
immunosuppressive effector(s). To the contrary, however, we
found that L-MSCs were no more effective than BM-MSCs in
inhibiting T cell proliferation and cytokine production in vitro
(Figure 2C) and that immunosuppression by L-MSCs also
relied on inflammatory cytokine-induced NO production (Fig-
ures S2A and S2B). Interestingly, administration of a NO
blocker 1400W in vivo obliterated the tumor-promoting effect
of BM-MSCs, but not L-MSCs (Figure S2C). Even with
1400W treatment, L-MSCs still enhanced tumor growth more
effectively than BM-MSCs (Figure S2C), indicating that NOc.
Figure 2. L-MSCs and BM-MSCs Inhibited Adaptive Immune Cells to a Similar Degree
(A) Influence of MSC coadministration on host adaptive immune cells. L-MSCs or BM-MSCs were coadministered with EL4 cells at a 2:5 ratio (MSCs: EL4 cells)
into C57BL/6 mice. At the indicated time points after tumor inoculation, tumors were excised and single-cell suspensions prepared. These tumor cells and
peripheral blood cells were stained for CD3, CD19, CD4, and CD8 and analyzed by flow cytometry.
(B) Serum levels of IFNg and IL-12 on day 12 in each group described in (A) were assayed by multiplexed bead-based immunoassay. Four mice per treatment
group were used and results (means ± SD) are representative of four independent experiments.
(C) BM-MSCs or L-MSCs were cocultured with splenocytes at graded ratios in the presence of anti-CD3 (1 mg/ml). After 2 days, cell proliferation was assayed by
3H-thymidine incorporation, and IFNg in the culture supernatants was measured by multiplexed bead immunoassay. Values are means ± SD of four replicate
wells from a representative of three experiments.
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L-MSCs.
L-MSCs Recruited More Myeloid Cells than BM-MSCs
Did in EL4 Transplantation Model
Recent studies have revealed that some innate immune
cells such as CD11b+Gr-1+ myeloid-derived suppressor cells
(MDSCs) and tumor-associatedmacrophages (TAMs) play a crit-
ical role in modulating immunity against tumors (Allavena et al.,
2008; Gabrilovich and Nagaraj, 2009; Yang et al., 2004). MDSCs
include two distinct subtypes: CD11b+Ly6G+ neutrophils and
CD11b+Ly6C+ monocytes, which function very differently in
cancer (Gabrilovich and Nagaraj, 2009), whereas TAMs include
inflammatory CD206 M1-type and anti-inflammatory CD206+
M2-type cells (Allavena et al., 2008). We therefore compared
the effects of L-MSCs and BM-MSCs on innate immune cells
in the EL4 syngeneic tumor transplantation model.
By monitoring these cells in peripheral blood and tumors over
several days after coinjection of EL4 cells and L-MSCs or BM-
MSCs, we found that while other innate immune cells (such asCellCD11c+ dendritic cells) were unaltered by BM-MSCs or
L-MSCs (data not shown), there was a great expansion of the
populations of CD11b+Ly6G+ neutrophils, CD11b+Ly6C+ mono-
cytes, and F4/80+ macrophages in both tumors and peripheral
blood, an effect that was dramatically greater with L-MSCs
than BM-MSCs (Figures 3A–3D and Figure S3). It has been re-
ported that MSCs can educate macrophages to preferentially
differentiate into M2-type cells (Zhang et al., 2010). In our exper-
imental setting, the ratio of CD206+ macrophages to CD206
macrophages in tumors was not different with or without MSC
coadministration (Figure 3C). When the F4/80+CD11b+ macro-
phages purified from fresh tumors were further examined for
their M1/M2 gene expression profile, we found that macro-
phages isolated from tumors coinjected with L-MSCs were
IL-12lowIL-10highTNFalowMHC-IIlow, comprising an M2-preferen-
tial gene signature, in comparison to control macrophages. Inter-
estingly, these L-MSC-associated macrophages differed slightly
from the traditional M2 type, since they expressed lower levels of
arginase 1 and interleukin 1 receptor antagonist (IL-1RA) and
comparable levels of iNOS and CD206, compared to controlStem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier Inc. 815
Figure 3. Recruitment of Monocytes, Macrophages, and Neutrophils by L-MSCs and BM-MSCs In Vivo
BM-MSCs or L-MSCs were coadministered with EL4 cells into C57BL/6 mice, as in Figure 1D. After 6, 9, or 12 days, single-cell suspensions prepared from tumor
tissues or from peripheral blood were analyzed for the frequency of CD11b+Ly6G+ neutrophils, CD11b+Ly6C+ monocytes, and F4/80+ macrophages. Flow
cytometry data of tumor-infiltrated myeloid cells from day 6 are shown (A–C), along withmeans ± SD of both tumor tissues and peripheral blood for all time points
(D). Four mice per treatment group were used and results are representative of four independent experiments.
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MSC-associated macrophages will lead to a better under-
standing of immune responses to tumors.
The increase in the frequency of the myeloid cells caused by
L-MSCs was detected earlier in tumors than in peripheral blood
(Figure 3D). In tumors, after reaching a maximum on day 6, the
frequency of myeloid cells decreased gradually, although total
numbers of myeloid cell were still high given the increase in
tumor mass. In contrast, the kinetics were delayed in peripheral
blood, with myeloid cell numbers cresting on day 9 (Figure 3D).
And L-MSCs were clearly more effective than BM-MSCs in re-
cruiting all myeloid cell types (CD11b+Ly6G+ neutrophils,
CD11b+Ly6C+ monocytes, and F4/80+ macrophages) to tumor
sites. To determine whether this differential recruitment of
myeloid cells is responsible for the striking difference in tumor
growth enhancement by L-MSCs and BM-MSCs, we next con-
ducted cell depletion experiments in vivo.
Monocytes/Macrophages, but Not Neutrophils, Are
Essential for the Tumor-Promoting Effect of L-MSCs
Sincemonocytes andmacrophages sharemany phenotypic and
functional similarity (Gordon and Taylor, 2005) but are distinct
from neutrophils, we depleted neutrophils or monocytes/macro-
phages to determine whether any of these cell types mediate
the tumor-promoting effect of MSCs. Using Ly6G neutralizing
antibody (clone 1A8) in vivo, we specifically depleted CD11b+
Ly6G+ neutrophils in tumor tissues as well as peripheral blood,
without affecting the numbers of CD11b+Ly6C+ monocytes or816 Cell Stem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier InF4/80+ macrophages (Figures 4A and 4B and Figures S4A and
S4B). Although CD11b+Ly6G+ granulocytic MDSCs have been
reported to participate in tumor-associated immunosuppression
and angiogenesis (Gabrilovich and Nagaraj, 2009; Murdoch
et al., 2008), depletion of this particular population of MDSCs in
our systemhadnoeffect on L-MSC-promoted tumor growth (Fig-
ure 4C), indicating that CD11b+Ly6G+ neutrophils are dispens-
able for the tumor growth enhancement induced by L-MSCs.
Next, we employed CD11b-DTR transgenic mice to ablate
monocytes/macrophages (Duffield et al., 2005). Administration
of diphtheria toxin (DT) resulted in depletion of most CD11b+
Ly6C+ monocytes and F4/80+ macrophages in both peripheral
and tumor-infiltrating sites (Figures 4D and 4E and Figures
S4C–S4E). Although neutrophils also express CD11b, the
frequency of CD11b+Ly6G+ cells was not reduced by DT admin-
istration, corroborating with recent studies (Barbalat et al., 2009;
Qian et al., 2009). Strikingly, we found that ablation of mono-
cytes/macrophages completely abolished the tumor-promoting
effect of L-MSCs (Figure 4F). Indeed, in the absence of mono-
cytes/macrophages, there was no difference between the
L-MSC and BM-MSC treatment groups, suggesting that mono-
cytes/macrophages are the key mediators of L-MSC-enhanced
tumor growth.
CCR2-Mediated Monocyte/Macrophage Trafficking Is
Critical for the Tumor-Promoting Effect of L-MSCs
As shown above, L-MSCsweremore effective than BM-MSCs in
recruiting monocytes/macrophages to tumor sites. Regardingc.
Figure 4. Monocytes/Macrophages, but Not Neutrophils, Were Required for Tumor-Promotion by L-MSCs
(A–C) Depletion of CD11b+Ly6G+ neutrophils did not alter the tumor-promoting activity of MSCs. BM-MSCs or L-MSCs were coadministered with EL4 cells into
C57BL/6 mice, as in Figure 1D, and Ly6G neutralizing Ab (1A8;150 mg per injection/mouse, intraperitoneally [i.p.]) was administered on days 4, 7, and 10 after cell
inoculation. On day 6, tumors were excised and single-cell preparations were analyzed by flow cytometry for the extent of depletion of different myeloid cell types
in tumors. Shown are representative flow cytometry data for tumor-bearing mice injected with EL4 without MSC coadministration (A) and averaged results for all
treatment groups (B). To determine the effect on tumor growth, we excised tumors from identically treated mice and weighed them on day 12 (C).
(D–F) Ablation of monocytes/macrophages completely abolished the tumor-promoting activity of MSCs. After coadministration of BM-MSCs or L-MSCswith EL4
cells, as in Figure 1D, into CD11b-DTRmice, diphtheria toxin (DT, 5 ng/g/injection) or vehicle (1% BSA in sterile water) was administered i.p. on days 4, 7, and 10,
and extent of myeloid cell depletion in tumor tissues was measured on day 6 (D and E). Tumors were weighed on day 12 (F). Four mice per treatment group were
used and results (means ± SD) are representative of three independent experiments.
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monocytes/macrophages, we speculated that chemotactic
factors governing monocyte/macrophage trafficking might be
involved.We therefore assessed various cytokines, chemokines,
and growth factors present in conditioned medium from L-MSC
and BM-MSC cultures. Using a Luminex-based multiplex bead
array system, we found that several cytokines and chemokines,
including IL-5, IL-6, CXCL-10 (IP-10), CXCL-1 (KC), CCL-2
(MCP-1), and V-EGF, were significantly higher in supernatant
from L-MSCs compared to BM-MSCs (Figure 5A). Most notably,
CCL-2, the major chemokine for monocyte trafficking, was
expressed at an extremely high level by L-MSCs, but not by
BM-MSCs (Figure 5A), suggesting that L-MSC-produced che-
mokines may play an important role in attracting monocytes/Cellmacrophages to tumor sites. Moreover, quantitative PCR
showed that, in addition to CCL-2, the transcript levels of
CCL-7 and CCL-12, the other two CCR2 ligands, were also
markedly higher in L-MSCs than in BM-MSCs (Figure S5A).
Importantly, when these CCR2 ligands were quantitatively
analyzed in tumors, they were expressedmainly by stromal cells,
but not by tumor cells (Figure S5B).
The chemokine receptor CCR2 is known to be expressed on
monocytes/macrophages (Kurihara et al., 1997). Our results
suggest that L-MSCs probably exert their tumor-promoting
effect by recruiting monocytes/macrophages to tumor sites
through production of CCR2 ligands. To examine this possibility,
we examined the chemotactic potential of supernatants
from L-MSC culture in vitro using a transwell assay. L-MSCStem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier Inc. 817
Figure 5. Tumor-Promoting Effect of L-MSCs Requires CCR2
(A) Overexpression of CCL-2 ligands by L-MSCs. Supernatants from cultures of BM-MSCs and L-MSCs from the same passage number were assayed for the
indicated cytokines by multiplexed bead array immunoassay. Values are means ± SD of four replicate wells from a representative of five different MSC lines.
(B) Chemotaxis by BM-derived monocytes in response to culture supernatants from L-MSCs or BM-MSCs was tested in a Transwell system, with or without the
addition of anti-CCR2 (10 mg/ml). After 3 hr incubation, cells that had migrated through membrane pores and into bottom wells were quantitated under
microscope. Values are means ± SD of three replicate wells from a representative of three experiments.
(C–E) Impact of CCR2 deficiency on myeloid cells in tumor-bearing mice. BM-MSCs or L-MSCs were coadministered with EL4 cells, as in Figure 1D, into WT
C57BL/6 mice or CCR2/mice, and myeloid cell frequency was examined on day 7. Representative flow cytometry data show the frequency of CD11b+Ly6G+
neutrophils, CD11b+Ly6C+ monocytes, and F4/80+ macrophages from tumor and peripheral blood of EL4-bearing control mice (C). Means and statistical
differences among all treatment groups in tumors of WT and CCR2-KO mice are given (D). Tumors were weighed on day 12 (E). Four mice per group were used
and results (means ± SD) are representative of three independent experiments.
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from monocytes than did BM-MSC supernatants (Figure 5B).
This chemotactic activity was largely CCR2 dependent since
it was significantly blocked by adding CCR2 blocking antibody.
We also performed CCL-2 knockdown in L-MSCs and found
that they were significantly less effective than wild-type
L-MSCs in attracting macrophages into EL4 tumors and pro-
moting tumor growth, suggesting that expression of this typical
CCR2 ligand by L-MSCs is involved in tumor promotion
(Figure S5C).
To definitively establish the roles of all L-MSC-overexpressed
CCR2 ligands (CCL-2, CCL-7, and CCL-12) in monocyte/
macrophage infiltration and tumor growth promotion in vivo,
we cotransplanted MSCs and tumor cells into CCR2-knockout818 Cell Stem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier In(CCR2-KO) C57BL/6 mice. We found that CCR2 deficiency led
to a significant reduction in monocyte/macrophage numbers in
both tumor tissues and peripheral blood, whereas neutrophil
frequency was mildly increased (Figures 5C and 5D and Fig-
ure S5D), an effect similar to that found with monocyte/
macrophage ablation in CD11b-DTR mice. These results
indicate that CCR2 is critical for trafficking of CD11b+Ly6C+
monocytes and F4/80+ macrophages, but not CD11b+Ly6G+
neutrophils. As expected, the tumor-promoting effects of
MSCs were abolished in CCR2-KO mice, manifested as almost
equal tumor masses in the L-MSC, BM-MSC, and control treat-
ment groups (Figure 5E). These results clearly demonstrate that
tumor promotion by L-MSCs occurs through CCR2-mediated
recruitment of monocytes/macrophages.c.
Figure 6. TNFa-Stimulated BM-MSCs Mimic the Characteristics of L-MSCs in Promoting Tumor Growth
(A) Lethally irradiated WT C57BL/6 mice were transplanted with bone marrow cells from GFP-transgenic mice (C57 background) via intrabone injection. Three
months later, thesemicewere injectedwith EL4 lymphoma cells (53 105 cells), andMSCswere isolated from the resultant tumors after 12 days. The phenotype of
EL4-derived MSCs was assayed by flow cytometry, as in Figure 1B, by gating on GFP+ cells. Results are representative of two independent experiments.
(B) Treatment with TNFa altered the cytokine production profile of BM-MSCs. Supernatants from cultured BM-MSCs treated with or without TNFa (20 ng/ml for
24 hr) were assayed for the indicated cytokines by multiplexed bead immunoassay. Results are representative of three different BM-MSC lines.
(C and D) TNFa-pretreated BM-MSCs enhanced the growth of EL4 tumorsmore significantly than did control BM-MSCs. BM-MSCs (23 105 cells), with or without
TNFa treatment (20 ng/ml for 24 hr), were coadministered with EL4 cells (5 3 105 cells) into C57BL/6 mice. Tumor sizes were measured at the indicated time
points after inoculation (C). Extent of F4/80+ macrophage infiltration in tumors from each group was examined by flow cytometry on day 6 (D).
(E) Depletion of monocytes/macrophages or deficiency in CCR2 prevented tumor promotion by TNFa-treated MSCs. In experiments conducted as in Figure 4F
and Figure 5E, the tumor-promoting capacity of TNFa-treated BM-MSCs was examined and compared to control BM-MSCs. Tumors were weighed on day 12.
Five mice per group were used and results (means ± SD) are representative of three independent experiments.
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Lymphoma Growth
MSCs are an important component of the tumor stroma, and
BM-MSCs are likely to be the source of tumor-resident MSCs.
Recent studies have shown that BM-MSCs can migrate into
tumors, guided by stimuli secreted from tumor cells, stromal
cells, and immune cells in the local tumor microenvironment
(Bergfeld and DeClerck, 2010; Studeny et al., 2004). To verify
that the tumor-resident MSCs are derived from BM-MSCs,
C57BL/6mice were lethally irradiated and reconstituted by intra-
bone injection of bone marrow from green fluorescent protein
(GFP)-transgenic mice. We found that a large proportion of
tumor-associated MSCs originated from GFP+ bone marrow
cells (Figure 6A and Figure S6A).CellThe major difference between L-MSCs and BM-MSCs is their
cytokine/chemokine production profile and therefore their
capacities to regulate monocyte/macrophage trafficking in vivo.
One of the key questions is what causes the change in BM-
MSCs after their arrival at the tumor microenvironment. It has
been well established that inflammation plays a critical role in
every stage of tumor progression, and inflammatory cytokines
in the tumor microenvironment are crucial in modulating the
functions of various types of tumor stromal cells and immune
cells (Grivennikov et al., 2010). Therefore, the changes in cyto-
kine/chemokine expression pattern in BM-MSCs and the subse-
quent enhancement of tumor progression could be caused by
inflammatory cytokines. When BM-MSCs were treated with
various inflammatory cytokines IFNg, TNFa, IL-1, IL-6, andStem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier Inc. 819
Cell Stem Cell
MSCs Promote Tumor Growth via MacrophagesGM-CSF, we found that only TNFa-treated BM-MSCs displayed
a profile of cytokine/chemokine production resembling that of
L-MSCs (Figure 6B and Figure 5A). In fact, as a master regulator
of tumor-associated inflammation through the NF-kB pathway,
TNFa plays a major role in the enhancement of tumor pro-
gression by its modulation of multiple tumor-related cell types
(Grivennikov and Karin, 2011).
When TNFa-pretreated BM-MSCs were tested for their
capacity to promote tumor growth in the EL4 tumor model, we
found that, like L-MSCs, they promoted faster tumor growth
(Figure 6C) and recruited more macrophages into the tumors
than did BM-MSCs (Figure 6D). Importantly, depletion of
monocytes/macrophages by DT administration in CD11b-DTR
mice completely abrogated the tumor-promoting activity of
TNFa-pretreated BM-MSCs (Figure 6E, left). Furthermore, their
tumor-promoting effect was also abolished in CCR2-KO mice
(Figure 6E, right). The similarities between TNFa-pretreated
BM-MSCs and L-MSCs strongly suggest that TNFa is prob-
ably responsible for converting normal tissue MSCs into
the tumor-promoting phenotype usually found in the tumor
microenvironment.
We next tested the persistence of CCL-2 production by MSCs
after stimulation with TNFa. BM-MSCs were stimulated with
TNFa for 24 hr, then washed to remove the cytokine, and subcul-
tured every day. CCL-2 production, assayed daily bymultiplexed
bead immunoassay, was found to gradually diminish to the same
level as in unstimulated controls by day 3 (Figure S6B). These
TNFa-pretreated MSCs not only did not become refractory to
restimulation by TNFa but, instead, produced a higher level of
CCL-2 than the control MSCs upon TNFa restimulation (data
not shown). This TNFa-induced CCL-2 production in BM-
MSCs was sufficient to initiate a significant tumor-promoting
effect in vivo. It is possible that early recruitment of macrophages
is essential for the lasting tumor-promoting effect of MSCs. In
experimental treatment of immune disorders, MSCs have been
found to disappear quickly after infusion (Lee et al., 2009; von
Bahr et al., 2012). Therefore, the long-lasting therapeutic effects
of MSCs are believed to be exerted largely through a lasting
influence on the host tissue microenvironment, rather than the
differentiation or persisting effect of MSCs.
In mice bearing either transplanted or spontaneous lym-
phomas, systemic levels of TNFa were readily detectable
(Figures S6C and S6D). To directly test the role of intrinsic
TNFa in the development of L-MSCs, we compared CCL-2+
LinlowSca-1+CD140a+ cells (representing L-MSC-like cells) by
flow cytometry in both wild-type and TNFa-KO mice bearing
transplanted EL4 lymphoma. We found many fewer L-MSC-
like cells in tumors from TNFa-KO mice, compared to those
from wild-type mice (Figure S6E), indicating that TNFa plays
a critical role in the generation of L-MSCs.
The MSC-Macrophage Interaction in Spontaneous
Lymphomas and Transplanted Solid Tumors
Using our lymphoma transplantation model, we found a link
between MSCs and macrophages in accelerating lymphoma
progression. We then tested whether such interplay also exists
in spontaneous lymphomas. In 12 spontaneous T cell lym-
phomas from p53/ mice and 15 spontaneous B cell lym-
phomas from gld/gld mice, there were significant positive cor-820 Cell Stem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier Inrelations between the numbers of tumor-infiltrated MSCs
(LinlowSca-1+CD140a+) and macrophages (F4/80+) (T cell
lymphomas: r = 0.715, p = 0.009; B cell lymphomas: r = 0.562,
p = 0.029), whereas no significant correlation was observed
between MSCs and CD11b+Ly6G+ neutrophils (Figure 7A and
Figures S7A and S7B). This further highlights the potentially
important interaction between MSCs and macrophages during
tumor development. It is important to point out that among the
spontaneous lymphomas, smaller tumors had significantly
greater frequencies of infiltrated MSCs than did larger tumors
(Figure S7C), indicating that MSCs might play a more important
role during the early stages of tumor development.
Lymphomas are distinct from other malignancies such as
carcinomas and melanomas in their characteristics. Therefore,
to generalize our findings in lymphomas to other cancer types,
we extended our experiments to B16 melanoma and 4T1 breast
carcinoma models. We found that TNFa-pretreated BM-MSCs
(mimicking L-MSCs) could also significantly promote B16 mela-
noma growth, and the tumor-promoting effect also disappeared
in the absence of CCR2 signaling (Figures 7B and 7C). Similar to
the lymphoma model, TNFa-treated BM-MSCs caused more
abundant accumulation of F4/80+ macrophages in the mela-
nomas as compared to control BM-MSCs (Figure 7D and Fig-
ure S7D). Much the same was observed in the 4T1 mouse breast
carcinoma model, with TNFa-pretreated BM-MSCs being more
effective than control MSCs in promoting tumor growth (Fig-
ure 7E) and recruiting F4/80+ macrophages at early-stage breast
tumor progression (Figure 7F). Altogether, these data demon-
strate that the inflammatory cytokine TNFa can render BM-
MSCs to become L-MSC-like cells, with the capability to recruit
macrophages to tumor sites and consequently enhance tumor
growth.
DISCUSSION
Our findings demonstrate a mechanism of promotion of tumor
progression: the interaction between tumor-resident MSCs
and immune cells. Based on our findings, we propose the
followingmodel to describe this effect (Figure 7G). During tumor-
igenesis, normal tissueMSCs such as BM-MSCs are recruited to
the tumor microenvironment and are continuously exposed to
the local immune cells and inflammatory factors, which may
instruct the BM-MSCs to adopt some new features, such as
the overexpression of certain cytokines/chemokines, especially
the CCR2 ligands. Via such chemotactic factors, the converted
tumor-resident MSCs are able to recruit more monocytes/
macrophages and neutrophils to the tumor sites. Additionally,
NO-mediated immunosuppression of adaptive immune cells
by MSCs may play a role in tumor progression, albeit a minor
one. These results thus establish a mechanistic link between
the two major types of tumor stromal cells—MSCs and
monocytes/macrophages—in driving tumorigenesis via the
CCR2-chemokine axis. Our findings provide important insights
into the role of MSCs in guiding the formation of the tumor micro-
environment, as well as the importance of inflammation in this
effect. Strategies that target MSC-monocyte/macrophage
crosstalk should provide a novel avenue of cancer therapy.
Immunosuppression and angiogenic activity induced by
TAMs and MDSCs are recognized as key mediators of tumorc.
Figure 7. The Interaction between MSCs and Macrophages in Spontaneous Lymphomas and Transplanted Solid Tumors
(A) Numbers of MSCs and macrophages were positively correlated in spontaneous lymphomas. Spontaneous T cell lymphomas and B cell lymphomas were
harvested from p53/ and gld mice, respectively. The frequencies of LinlowSca-1+CD140a+ cells (representing tissue MSCs) and F4/80+ macrophages were
analyzed by flow cytometry.
(B–D) Effects of BM-MSCs on tumor growth in a B16-F0melanomamodel. Control BM-MSCs or TNFa-treated BM-MSCswere coadministered with B16-F0 cells
into C57BL/6mice subcutaneously, as in Figure 1D. Tumor size wasmeasured at the indicated time points postinoculation (B). Deficiency in CCR2 eliminated the
tumor-promoting activity of TNFa-treatedMSCs, as indicated by tumor weights on day 12 (C). Similar to the lymphomamodel, F4/80+macrophage infiltration into
tumors wasmuch greater in mice coadministered TNFa-pretreatedMSCs, as revealed by flow cytometry on day 8 (D). Four mice per groupwere used and results
(means ± SD) are representative of three independent experiments.
(E and F) Breast carcinoma 4T1 model. Control BM-MSCs or TNFa-treated BM-MSCs were coadministered with 4T1 cells into the mammary gland fat pad of
Balb/c mice. Tumor size was measured at the indicated time points postinoculation (E). Extent of F4/80+ macrophage infiltration on day 7 was detected by
immunohistochemical staining (F). Five mice per group were used and results (means ± SD) are representative of two independent experiments.
(G) Proposedmodel depicting the mechanism of tumor growth promotion byMSCs. TNFa, and possibly other proinflammatory cytokines, induce tumor-resident
MSCs to express CCR2-chemokines, which recruit monocytes/macrophages that are directly responsible for augmenting tumor growth, by previously described
mechanisms.
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2009). Our present findings demonstrate that MSCs affect both
TAMs and MDSCs. However, only CD11b+Ly6C+ monocytic
MDSCs and macrophages, but not the CD11b+Ly6G+ granulo-
cytic MDSCs, were found to be pivotal for the tumor-promoting
activity of L-MSCs. The granulocytic MDSCs, while having little
effect on the growth of tumors, may affect other aspects of tumor
progression, such as metastasis, which was not investigated in
the current study. In fact, these cells have been shown toCellpromote mammary carcinoma metastasis in the absence
of TGFb signaling (Yang et al., 2008). Therefore, the effect of
MSCs on myeloid cells appears to be a key paradigm in the
biology ofMSCs. Blockage of such interactionsmight be a useful
strategy for treating stromal cell-related diseases.
Previous studies showed that CCL-2 is essential in suppres-
sion of B cell function and CD4+ T cell function in experimental
autoimmune encephalomyelitis byMSCs inmice. Such suppres-
sion was dependent on MSC-driven generation of CCL-2Stem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier Inc. 821
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et al., 2008, 2009). It remains unknown whether or not these
effects are also related to monocyte/macrophage trafficking.
Moreover, it has been found that during bacterial infections,
stimulation through toll-like receptors caused BM-resident
MSCs to produce abundant CCL-2, which induced monocyte
emigration from bone marrow to the periphery (Shi et al.,
2011). Thus, the MSC-CCL-2-monocyte axis is probably also
physiologically important in other diseases in addition to tumor
progression.
Inflammation has been long regarded as a key regulator of
cancer progression according to the observations that some
cancers frequently occurred with infectious diseases and other
chronic inflammations, as well as the reduced cancer incidence
in individuals taking anti-inflammation medications (Coussens
and Werb, 2002; Mantovani et al., 2008; Trinchieri, 2012).
Inflammation provides various immune cells infiltrated into
tumors and overexpressed inflammatory cytokines, which
fundamentally modulate the tumor stroma—‘‘soil’’ of the tumor
microenvironment (Grivennikov et al., 2010). In this study, we
show evidence that healthy stromal cells such as BM-MSCs
could be educated into the tumor-resident stromal cell pheno-
type by inflammatory cytokine-TNFa, in producing chemotactic
and growth factors, and enhancing tumor growth via monocyte/
macrophage recruitment. Thus, inflammation increases the
tumor malignancy through decoration of the tumor stromal
MSCs, creating a crucial link between the tumor stroma and
tumor-infiltrating immune cells. Furthermore, the modulation of
stromal cells by resident inflammation may also implicate other
chronic diseases such as liver fibrosis and rheumatoid arthritis,
in which stromal cells have been shown to exert a leading role in
the disease progression (Lefe`vre et al., 2009; Li et al., 2009;
Zeisberg et al., 2007).
MSC-based therapies hold great promise for the treatment of
many different diseases (Giordano et al., 2007). Currently,
however, there is a lack of standardized criteria for selecting
MSCs for safe clinical use (Prockop et al., 2010; Wagner et al.,
2009). Based on the results of the present study, the cytokine
and chemokine production profiles of MSCs should be carefully
considered when choosing MSCs for patient use. In addition,
silencing CCR2 chemokines may benefit MSC-based cancer
target therapy (Mueller et al., 2011; Ren et al., 2008a; Sarkar
et al., 2010). While further investigation is needed to fully under-
stand the implications of our findings, CCR2-mediated mono-
cyte/macrophage recruitment is likely to be important in various
pathological conditions involving MSCs and other stromal cells.
A better understanding of the mechanisms underlying this
process should lead to better therapeutic application of MSCs.EXPERIMENTAL PROCEDURES
Animals
C57BL/6, Balb/c, p53+/, p53/, Gld/gld, CD11b-DTR, TNFa/, and
CCR2/ mice were obtained from the Jackson Laboratory. Mlh1/ mice
were described previously (Shao et al., 2004). Mice were housed in a specific
pathogen-free colony in the animal facilities of Shanghai Jiao Tong University
School ofMedicine andRutgers University. The animal protocols for the exper-
iments described in this paper were approved by the Institutional Animal Care
and Use Committee of Rutgers University and by the Institutional Animal Care
and Use Committee of the Institute of Health Sciences, Shanghai Institutes for822 Cell Stem Cell 11, 812–824, December 7, 2012 ª2012 Elsevier InBiological Sciences, and Shanghai Jiao Tong University School of Medicine.
The mice were matched for age and gender in each experiment.
Antibodies and Reagents
Fluorochrome-conjugated antibodies against CD3, CD4, CD8, CD19,
Ly6G, Ly6C, CD11b, F4/80, CD140a, and CD206 were from eBioscience.
Fluorochrome-conjugated antibodies against CD45, CD11c, CD31, C-kit,
CD29, CD44, and Sca-1 were from BD Biosciences. Fluorochrome-
conjugated antibodies against vimentin and FSP1 were obtained from Santa
Cruz Biotechnology and EMD Millipore, respectively. Antibody against
F4/80 for immunohistochemical analysis was from Abcam. Ly6G neutraliz-
ing antibody 1A8 was from Biolegend. Diphtheria toxin, collagenase, and
hyaluronidase were purchased from Sigma.
Isolation of MSCs from BM, Tumors, and Skin
L-MSCs, BM-MSCs, and skin-derived MSCs were generated from sponta-
neous lymphomas in mutant mice, mouse bone marrow, and mouse ears,
respectively. Spontaneous lymphomas were characterized according to the
previous references (Davidson et al., 1998; Donehower et al., 1992; Morse
et al., 2002). Tumors with diameters <7 mm are classified small, and those
with diametersR7mm are considered large. Briefly, the tissues were digested
by type I collagenase (0.5 mg/ml) and hyaluronidase (0.1 mg/ml) at 37C for
3 hr and the cells from different sources were cultured in a-MEMmedium sup-
plemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 g/ml
streptomycin (all from Invitrogen). Nonadherent cells were removed after 24 hr,
and CD45 cells were purified from adherent cells by immunomagnetic sepa-
ration using mouse CD45 microbeads (Miltenyi Biotec), and then maintained
with medium replenishment every 3 days. All MSCs (used before the tenth
passage) were examined to exclude hematopoietic stem (progenitor) cells
and lineage cell surface makers. The ‘‘stemness’’ of all MSCs was determined
by their capability to differentiate into adipocytes and osteoblasts (Ren et al.,
2008b), as well as by their expression of cell surface differentiation markers.
Tumor Transplantation
MSCs (1 3 105 [low dose] or 2 3 105 cells [high dose] for the EL4 lymphoma
model, 1 3 105 cells for the B16-F0 melanoma model, and 1 3 106 cells
for the breast carcinoma model) were coinjected with tumor cells (5 3
105 EL4 cells, 2.5 3 105 B16-F0 cells, and 2 3 105 4T1 cells) into C57BL/6
mice (EL4 and B16-F0 models) or Balb/c mice (4T1 model) intramuscularly
(EL4 model), subcutaneously (B16-F0), or in the intramammary gland fat pad
(4T1). At various time points, tumor sizes were measured and the immune
cell frequency in tumors or peripheral blood was analyzed by flow cytometry
or immunohistochemical staining. On day 12 (EL4 model and B16-F0 model)
or day 24 (4T1 model) after tumor cell administration, the resultant tumors
were excised and weighed. Each experimental group included at least four
mice. All experiments were replicated at least three times.
Immunofluorescence Staining and Flow Cytometry
For surface marker analysis, cells were suspended in staining buffer (PBS,
2% FBS) at a concentration of 2 3 106 cells/ml and 100 ml of suspension
was incubated with fluorescently labeled antibodies for 30 min on ice. Cells
were washed twice with staining buffer. Fluorescence intensity was measured
by flow cytometry (FACSCalibur, BD Immunocytometry).
Detection of Cytokines
Cytokine levels in culture supernatants or serum were assayed by mul-
tiplexed bead array immunoassay using Luminex Technology according to
the manufacturer’s protocol (Bio-Plex, Bio-Rad Laboratories).
Immunohistochemistry
Tumors were washed thoroughly in PBS and fixed in 10% PBS-buffered
formalin. Tissues were embedded in paraffin, and 5–6 mm sections were cut,
deparaffinized, and stained with antibody according to the protocol provided
by the manufacturer.
Statistical Analysis
Statistical significance was assessed by nonpaired two-tailed Student’s t test
or nonparametric Spearman correlation for the relationship between MSCc.
Cell Stem Cell
MSCs Promote Tumor Growth via Macrophagesfrequency and myeloid cell frequency in spontaneous lymphomas; *p < 0.05,
**p < 0.01, and ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes seven figures and Supple-
mental Experimental Procedures and can be found with this article online at
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